133 related articles for article (PubMed ID: 19329208)
1. Epigenetic modulation of radiation response in human cancer cells with activated EGFR or HER-2 signaling: potential role of histone deacetylase 6.
Kim IA; No M; Lee JM; Shin JH; Oh JS; Choi EJ; Kim IH; Atadja P; Bernhard EJ
Radiother Oncol; 2009 Jul; 92(1):125-32. PubMed ID: 19329208
[TBL] [Abstract][Full Text] [Related]
2. The HDAC inhibitor LBH589 induces ERK-dependent prometaphase arrest in prostate cancer via HDAC6 inactivation and down-regulation.
Chuang MJ; Wu ST; Tang SH; Lai XM; Lai HC; Hsu KH; Sun KH; Sun GH; Chang SY; Yu DS; Hsiao PW; Huang SM; Cha TL
PLoS One; 2013; 8(9):e73401. PubMed ID: 24023871
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.
Bali P; Pranpat M; Bradner J; Balasis M; Fiskus W; Guo F; Rocha K; Kumaraswamy S; Boyapalle S; Atadja P; Seto E; Bhalla K
J Biol Chem; 2005 Jul; 280(29):26729-34. PubMed ID: 15937340
[TBL] [Abstract][Full Text] [Related]
4. Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells.
Edwards A; Li J; Atadja P; Bhalla K; Haura EB
Mol Cancer Ther; 2007 Sep; 6(9):2515-24. PubMed ID: 17876048
[TBL] [Abstract][Full Text] [Related]
5. Isotype-Specific Inhibition of Histone Deacetylases: Identification of Optimal Targets for Radiosensitization.
Kim JH; Moon SH; No M; Kim JJ; Choi EJ; Cho BJ; Kim JS; Kim IH; Kim IA
Cancer Res Treat; 2016 Jul; 48(3):1130-40. PubMed ID: 26582395
[TBL] [Abstract][Full Text] [Related]
6. Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90.
Fiskus W; Ren Y; Mohapatra A; Bali P; Mandawat A; Rao R; Herger B; Yang Y; Atadja P; Wu J; Bhalla K
Clin Cancer Res; 2007 Aug; 13(16):4882-90. PubMed ID: 17699868
[TBL] [Abstract][Full Text] [Related]
7. Sensitization to gamma-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells.
Zhang F; Zhang T; Teng ZH; Zhang R; Wang JB; Mei QB
Cancer Biol Ther; 2009 May; 8(9):823-31. PubMed ID: 19270532
[TBL] [Abstract][Full Text] [Related]
8. The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.
LaBonte MJ; Wilson PM; Fazzone W; Russell J; Louie SG; El-Khoueiry A; Lenz HJ; Ladner RD
Cancer Res; 2011 May; 71(10):3635-48. PubMed ID: 21464044
[TBL] [Abstract][Full Text] [Related]
9. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.
LaBonte MJ; Wilson PM; Fazzone W; Groshen S; Lenz HJ; Ladner RD
BMC Med Genomics; 2009 Nov; 2():67. PubMed ID: 19948057
[TBL] [Abstract][Full Text] [Related]
10. LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/STAT3/Akt pathway.
Song X; Wang J; Zheng T; Song R; Liang Y; Bhatta N; Yin D; Pan S; Liu J; Jiang H; Liu L
Mol Cancer; 2013 Oct; 12(1):114. PubMed ID: 24093956
[TBL] [Abstract][Full Text] [Related]
11. CG0006, a novel histone deacetylase inhibitor, induces breast cancer cell death via histone-acetylation and chaperone-disrupting pathways independent of ER status.
Kim HM; Kim CS; Lee JH; Jang SJ; Hwang JJ; Ro S; Hyun YL; Choi J
Breast Cancer Res Treat; 2011 Nov; 130(2):365-75. PubMed ID: 21184271
[TBL] [Abstract][Full Text] [Related]
12. Targeting epidermal growth factor receptor-associated signaling pathways in non-small cell lung cancer cells: implication in radiation response.
Choi EJ; Ryu YK; Kim SY; Wu HG; Kim JS; Kim IH; Kim IA
Mol Cancer Res; 2010 Jul; 8(7):1027-36. PubMed ID: 20587532
[TBL] [Abstract][Full Text] [Related]
13. Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases.
Choi EJ; Cho BJ; Lee DJ; Hwang YH; Chun SH; Kim HH; Kim IA
BMC Cancer; 2014 Jan; 14():17. PubMed ID: 24418474
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitor-mediated radiosensitization of human cancer cells: class differences and the potential influence of p53.
Kim IA; Shin JH; Kim IH; Kim JH; Kim JS; Wu HG; Chie EK; Ha SW; Park CI; Kao GD
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):940-9. PubMed ID: 16467109
[TBL] [Abstract][Full Text] [Related]
15. HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA).
Mehdi O; Françoise S; Sofia CL; Urs G; Kevin Z; Bernard S; Igor S; Anabela CD; Dominique L; Eric M; Ali O
Pancreatology; 2012; 12(2):146-55. PubMed ID: 22487525
[TBL] [Abstract][Full Text] [Related]
16. The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258.
Vallo S; Mani J; Stastny M; Makarević J; Juengel E; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
Invest New Drugs; 2013 Apr; 31(2):265-72. PubMed ID: 22801803
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer.
Geng L; Cuneo KC; Fu A; Tu T; Atadja PW; Hallahan DE
Cancer Res; 2006 Dec; 66(23):11298-304. PubMed ID: 17145876
[TBL] [Abstract][Full Text] [Related]
18. Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro.
Chao H; Wang L; Hao J; Ni J; Chang L; Graham PH; Kearsley JH; Li Y
Cancer Lett; 2013 Feb; 329(1):17-26. PubMed ID: 22995071
[TBL] [Abstract][Full Text] [Related]
19. Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status.
Kimple RJ; Vaseva AV; Cox AD; Baerman KM; Calvo BF; Tepper JE; Shields JM; Sartor CI
Clin Cancer Res; 2010 Feb; 16(3):912-23. PubMed ID: 20103665
[TBL] [Abstract][Full Text] [Related]
20. Targeting HER2 signaling pathway for radiosensitization: alternative strategy for therapeutic resistance.
No M; Choi EJ; Kim IA
Cancer Biol Ther; 2009 Dec; 8(24):2351-61. PubMed ID: 19923913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]